Civil action against BioAlliance Pharma gets rejected

NewsGuard 100/100 Score

BioAlliance Pharma SA (Paris:BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal.

In 2008, Eurofins Pharma US Holding Inc. and one of its affiliates Viralliance Inc (“Eurofins”) had filed a civil action against BioAlliance (Press release of BioAlliance 14 October 2008). This US action concerned the diagnostic technology (Phenoscript® test of HIV drug resistance) transferred by BioAlliance Pharma to Eurofins.

Furthermore, BioAlliance Pharma instituted legal proceedings against Eurofins in Paris in January 2009 for non-development of the technology and harm of its image.

BioAlliance was advised by Ron Soffer, Attorney at Law, Member of the Paris Bar.

http://www.bioalliancepharma.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates